Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-05-25
2008-12-30
Mosher, Mary E (Department: 1648)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C424S545000
Reexamination Certificate
active
07470666
ABSTRACT:
The present invention relates to use of Ulinastatin and its pharmaceutical composition for treating and/or preventing Severe Acute Respiratory Syndrome (SARS). Ulinastatin is effective for treating and/or preventing SARS, particularly Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS). Ulinastatin is generally used as the pharmaceutical composition, preferably in the form of freeze-dried powder or aqueous solution for injection.
REFERENCES:
patent: 0 327 999 (1992-06-01), None
patent: 0327999 (1992-06-01), None
patent: 2000336041 (2000-12-01), None
patent: 20000335041 (2000-12-01), None
Yin et al, “Protective effects of ulinastatin on acute lung injury induced by acute necrotizing pancreatitis in rats.” Shijie Huaren Xiaohua Zazhi (2002), 10(5), 558-561 (Abstract only cited).
Li et al, “Effects of ulinastatin on interleukin-8 during one-lung ventilation in surgery.” Aizheng (2003), 22(10), 1074-1076 (Abstract only cited).
Isobe et a, “Inhibition of tumor necrosis factor-a production by urinary trypsin inhibitor.” International Congress Series (2003), 1255(Biological Response to Planned and Unplanned Injuries), 69-74 (Abstract only cited).
Nicholls et al, “Lung pathology of fatal severe acute respiratory syndrome,” Lancet, vol. 361, Issue 9371, May 24, 2003, pp. 1773-1778.
Wong et al, “Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome.” Clinical and experimental immunology Apr. 2004, 136 (1) p. 95-103.
Ng et al, “Inflammatory cytokine profile in children with severe acute respiratory syndrome.” Pediatrics Jan. 2004, 113 (1 Pt 1) pe7-14.
Cai et al. Circulatory Shock 43(2): 71-78, 1994, abstract only cited.
Manamiya et al. Sasshi Journal. Nihon Kyobu Geka Gakkai 41(12): 2364-2371, abstract only cited.
Manamiya et al. Sasshi Journal. Nihon Kyobu Geka Gakkai 41(12): 2364-2371, abstract only cited. (2003).
Cai, Ming et al., “Effects of Free Radical Scavengers, Methylprednisolone, and Ulinastatin on Acute Xanthine and Xanthine Oxidase-Induced Lung Injury in Rats,” Dept. of Anesthesiology, Nippon Med. School, Tokyo, Japan, pp. 71-78, 1994.
Fu Heliang
Miao Piqu
Wang Xiaoyan
Xie Yongli
Guangdong Techpool Biochem. Pharma. Co., Ltd.
Mosher Mary E
Ohlandt Greeley Ruggiero & Perle LLP
Rauchfuss, Jr. George W.
Ruggiero Charles N.J.
LandOfFree
Use of Ulinastatin and its pharmaceutical composition for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of Ulinastatin and its pharmaceutical composition for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of Ulinastatin and its pharmaceutical composition for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4044448